Sugi Predict

Sugi Predict / Compounds / SCHEMBL10160949

SCHEMBL10160949

SCHEMBL10160949

NC(=O)c1cc(-c2cnc(Nc3nc4c(s3)CCC4)c3nccn23)co1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPKAPK5 Q8IW41 9/20 0.58
▸ RAB9A P51151 7/20 0.37
▸ SMN1; SMN2 Q16637 5/20 0.37
▸ GAA P10253 3/20 0.37
▸ KMT2A Q03164 2/20 0.37
▸ MITF O75030 1/20 0.37
▸ FGFR3 P22607 1/20 0.34
▸ KDR P35968 1/20 0.34
▸ TTK P33981 1/20 0.34
▸ NPC1 O15118 6/20 0.34
▸ ALDH1A1 P00352 5/20 0.34
▸ MAPT P10636 4/20 0.34
▸ NFKB1 P19838 2/20 0.34
▸ NFKB2 Q00653 2/20 0.34
▸ RELA Q04206 2/20 0.34
▸ PKM P14618 2/20 0.34
▸ HSD17B10 Q99714 2/20 0.34
▸ TP53 P04637 2/20 0.34
▸ TSHR P16473 1/20 0.34
▸ CASP1 P29466 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10160953 0.85 MAPKAPK5 (0.57) MAPKAPK5TTK
SCHEMBL279923 0.79 MAPKAPK5 (0.64) MAPKAPK5TTK
SCHEMBL274912 0.78 MAPKAPK5 (0.61) MAPKAPK5TTK
SCHEMBL274878 0.78 MAPKAPK5 (0.61) MAPKAPK5TTKALDH1A1
SCHEMBL279482 0.77 MAPKAPK5 (0.62) MAPKAPK5TTK
SCHEMBL10160892 0.77 MAPKAPK5 (0.65) MAPKAPK5
SCHEMBL10160883 0.77 MAPKAPK5 (0.65) MAPKAPK5SMN1; SMN2KDR
SCHEMBL279480 0.77 MAPKAPK5 (0.60) MAPKAPK5TTKALDH1A1
SCHEMBL279441 0.77 MAPKAPK5 (0.60) MAPKAPK5TTKALDH1A1
SCHEMBL2060355 0.76 MAPKAPK5 (0.41) MAPKAPK5RAB9ASMN1; SMN2GAAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9006237-B2 Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases JANSSEN PHARMACEUTICA NV (BE) 2015-04-14 — — US disclosed
US-20120232075-A1 Fused Pyrazine Compounds Useful for the Treatment of Degenerative and Inflammatory Diseases ANDREWS MARTIN JAMES INGLIS (BE) 2012-09-13 — — US disclosed
US-8148369-B2 Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases JANSSEN PHARMACEUTICA NV (BE) 2012-04-03 — — US disclosed
US-20090012078-A1 Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases GALAPAGOS, N.V. (BE) 2009-01-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012078-A1 Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases TNF, LITAF, CNKSR1 MAPKAPK5 307/4885RAB9A 2142/4885SMN1; SMN2 1423/4885
US-20120232075-A1 Fused Pyrazine Compounds Useful for the Treatment of Degenerative and Inflammatory Diseases TNF, LITAF, CNKSR1 MAPKAPK5 307/4885RAB9A 2142/4885SMN1; SMN2 1423/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.